Narsoplimab

Description: Narsoplimab (OMS 721) is a selective whole-human immunoglobulin gamma-4 (IgG4) monoclonal antibody and a mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor that binds MASP-2 to prevent lectin pathway activation and inhibit the agglutinin pathway. It is used to study diseases associated with hematopoietic stem cell transplantation in adults. Target: SARS-CoV. References: Gao T, et, al. Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation. Signal Transduct Target Ther. 2022 Sep 14,7(1):318.